Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

NCT02833714 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT02833714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02833714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Observational
Overall status
Terminated
Start date
January 31, 2016
Completion date
December 21, 2016
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis